Rhythm Pharmaceuticals Inc (RYTM) — Cash Flow-to-Debt Ratio
Rhythm Pharmaceuticals Inc (RYTM) has a Cash Flow-to-Debt Ratio of -0.07x as of December 2025, meaning its operating cash flow of $-25.39 Million could theoretically repay 0% of its total liabilities ($342.12 Million) in one year. See financial flexibility index of Rhythm Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rhythm Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Rhythm Pharmaceuticals Inc across 14 annual periods. For the full cash flow conversion analysis, see how efficiently does Rhythm Pharmaceuticals Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Rhythm Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Rhythm Pharmaceuticals Inc. Check cash flow quality index of Rhythm Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | $-115.67 Million | $342.12 Million | ▲ +32.4% |
| 2024 | -0.50x | $-113.88 Million | $227.72 Million | ▲ +40.1% |
| 2023 | -0.84x | $-136.16 Million | $162.99 Million | ▲ +43.1% |
| 2022 | -1.47x | $-173.43 Million | $118.22 Million | ▲ +54.4% |
| 2021 | -3.22x | $-146.00 Million | $45.37 Million | ▲ +45.8% |
| 2020 | -5.94x | $-121.98 Million | $20.55 Million | ▼ -33.0% |
| 2019 | -4.46x | $-122.75 Million | $27.50 Million | ▼ -0.4% |
| 2018 | -4.45x | $-62.06 Million | $13.95 Million | ▼ -4.9% |
| 2017 | -4.24x | $-29.46 Million | $6.95 Million | ▲ +7.9% |
| 2016 | -4.61x | $-23.22 Million | $5.04 Million | ▼ -248.1% |
| 2015 | -1.32x | $-6.98 Million | $5.27 Million | ▲ +90.3% |
| 2014 | -13.60x | $-7.51 Million | $552.00K | ▼ -5271.1% |
| 2013 | -0.25x | $-19.16 Million | $75.65 Million | ▲ +21.6% |
| 2012 | -0.32x | $-17.83 Million | $55.21 Million | — |